1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 first-in-human study of Abbv-383, a BCMA x CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Voorhees, P. M.; D'Souza, A.; Weisel, K.; Hurd, D. D.; Teipel, R.; Chung, A.; Rodriguez, C.; Tuchman, S. A.; Korde, N.; Safah, H.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell mobilization characteristics for transplant eligible patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib, lenalidomide, dexamethasone, and daratumumab (KRd-Dara)
    Meeting Abstract

    Bhutani, M.; Robinson, M.; Atrash, S.; Watts, N.; Paul, B.; Chhabra, S.; Korde, N.; Begic, X.; Foureau, D. M.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Transient M-proteins: Epidemiology, causes, and the impact of mass spectrometry: The iStopMM study
    Meeting Abstract

    Palmason, R.; Berlanga, O.; Sigurdsson, J. K.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Ekberg, S.; Crowther, M.; Levy, M.; Reed, E. R.; Þórir Oskarsson, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
    Meeting Abstract

    Ziccheddu, B.; Diamond, B.; Maclachlan, K. H.; Taylor, J.; Boyle, E. M.; Arango Ossa, J. E.; Jacob, J.; Affer, M.; Totiger, T. M.; Coffey, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Individualized treatment-adjusted risk stratification in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A. R.; Derkach, A.; Ziccheddu, B.; Weinhold, N.; Maclachlan, K. H.; Diamond, B.; Davies, F. E.; Boyle, E.; Walker, B. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking the earliest genomic events in multiple myeloma life-history
    Meeting Abstract

    Cirrincione, A.; Ziccheddu, B.; Maclachlan, K. H.; Poos, A. M.; Chojnacka, M.; Diamond, B.; Boyle, E. M.; Blaney, P.; Gagler, D.; Zhang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) NEX T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Costa, L. J.; Kumar, S. K.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B. A.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P. L.; Limones, J.; more...
    Blood (2022)

    Fulltext@MSK | Save